I hosted another of our Compliance Week editorial roundtables last week, this time co-hosted by Deloitte and looking particularly at compliance challenges in the pharmaceutical sector. At first I wasn’t sure how the discussion might unfold; Compliance Week normally doesn’t delve too deeply into any single industry’s compliance regime, because each sector has unique burdens that don’t always carry much meaning for other industries. In a sector as heavily regulated as the drug business, one would think that isolation would very much be the case.
